BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 21611920)

  • 1. [New therapeutic options for advanced thyroid cancer].
    Willhauck MJ; Schott M; Kreissl MC; Fassnacht M; Spitzweg C
    Dtsch Med Wochenschr; 2011 Jun; 136(22):1165-8. PubMed ID: 21611920
    [No Abstract]   [Full Text] [Related]  

  • 2. Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer.
    Fagin JA; Tuttle RM; Pfister DG
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2621-4. PubMed ID: 20525911
    [No Abstract]   [Full Text] [Related]  

  • 3. Sorafenib and sunitinib.
    Kim A; Balis FM; Widemann BC
    Oncologist; 2009 Aug; 14(8):800-5. PubMed ID: 19648603
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeted molecular therapies in thyroid carcinoma.
    Romagnoli S; Moretti S; Voce P; Puxeddu E
    Arq Bras Endocrinol Metabol; 2009 Dec; 53(9):1061-73. PubMed ID: 20126863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
    Massicotte MH; Brassard M; Claude-Desroches M; Borget I; Bonichon F; Giraudet AL; Do Cao C; Chougnet CN; Leboulleux S; Baudin E; Schlumberger M; de la Fouchardière C
    Eur J Endocrinol; 2014 Apr; 170(4):575-82. PubMed ID: 24424318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New therapeutic regimes in metastasic renal-cell carcinoma].
    Bierer S; Hertle L; Nitschmann S
    Internist (Berl); 2008 Jan; 49(1):114-7. PubMed ID: 18704353
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapy for metastatic RCC--questions remain.
    Breau RH; Leibovich BC
    Nat Rev Urol; 2009 Nov; 6(11):580-1. PubMed ID: 19890336
    [No Abstract]   [Full Text] [Related]  

  • 8. Novel molecular targeted therapies for refractory thyroid cancer.
    Perez CA; Santos ES; Arango BA; Raez LE; Cohen EE
    Head Neck; 2012 May; 34(5):736-45. PubMed ID: 21544895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health policy: The UK 'postcode lottery' in renal cell carcinoma.
    Larkin J; Gore M
    Nat Rev Urol; 2009 Dec; 6(12):636-8. PubMed ID: 19956190
    [No Abstract]   [Full Text] [Related]  

  • 10. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
    Stein MN; Flaherty KT
    Clin Cancer Res; 2007 Jul; 13(13):3765-70. PubMed ID: 17606705
    [No Abstract]   [Full Text] [Related]  

  • 11. [New drugs; sunitinib and sorafenib].
    Bellersen L
    Ned Tijdschr Geneeskd; 2008 Feb; 152(8):469-70; author reply 470. PubMed ID: 18363211
    [No Abstract]   [Full Text] [Related]  

  • 12. Kidney cancer: Does hypothyroidism predict clinical outcome?
    Rini B
    Nat Rev Urol; 2011 Jan; 8(1):10-1. PubMed ID: 21116300
    [No Abstract]   [Full Text] [Related]  

  • 13. Tyrosine kinase inhibitors and the thyroid.
    Sherman SI
    Best Pract Res Clin Endocrinol Metab; 2009 Dec; 23(6):713-22. PubMed ID: 19942148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer.
    Lin CI; Whang EE; Lorch JH; Ruan DT
    Surgery; 2012 Dec; 152(6):1142-9. PubMed ID: 23158184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib.
    Marotta V; Di Somma C; Rubino M; Sciammarella C; Modica R; Camera L; Del Prete M; Marciello F; Ramundo V; Circelli L; Buonomano P; Colao A; Faggiano A
    Endocrine; 2015 Aug; 49(3):854-8. PubMed ID: 25305056
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeted therapies in the treatment of advanced/metastatic NSCLC.
    Pallis AG; Serfass L; Dziadziusko R; van Meerbeeck JP; Fennell D; Lacombe D; Welch J; Gridelli C
    Eur J Cancer; 2009 Sep; 45(14):2473-87. PubMed ID: 19596191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer.
    Takami HE
    Endocr J; 2011; 58(3):151-3. PubMed ID: 21383525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New weapons to snuff out kidney cancer.
    Wetherbee SL
    Nursing; 2006 Dec; 36(12 Pt.1):58-63; quiz 64. PubMed ID: 17135925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. About tyrosine kinase inhibitors (TKIs) in prostate cancer: where do we go from here?
    Aragon-Ching JB; Dahut WL
    Ann Oncol; 2010 Jan; 21(1):183-4. PubMed ID: 19903718
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeted therapy in advanced non-small-cell lung cancer.
    Gettinger S
    Semin Respir Crit Care Med; 2008 Jun; 29(3):291-301. PubMed ID: 18506667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.